Cardiovascular diseases are a leading cause of morbidity and mortality in most developed
countries of the world. Pharmaceuticals, illicit drugs, and toxins can significantly contribute to …

Combined oral contraceptives (COC) are the most often used treatment modality for
polycystic ovary syndrome (PCOS). Undisputedly, COC suppress androgen production, thus …

Context: Polycystic ovary syndrome (PCOS) is associated with increased risk of
cardiovascular morbidity, whereas statins are proven to reduce cardiovascular mortality and …

BACKGROUND Polycystic ovary syndrome (PCOS) is the most common endocrine disorder
of young women. First-line treatment is often the oral contraceptive pill (OC), but evidence …

In the chronic treatment of polycystic ovary syndrome (PCOS), oral contraceptive pills
(OCPs) are commonly used to induce regular menses, protect the endometrium and …

Background: The role of inflammation in the pathogenesis of cardiovascular disease is well
established. C‐reactive protein (CRP) is the strongest independent predictor of myocardial …

Introduction: The risk-benefit profile of any pharmacologic agent must be evaluated against
risks connected with the events to be avoided. This is especially true in the case of hormonal …

Aim. Compare the effects of a combined contraceptive pill (OCP) in combination with myo-
inositol (MI) on endocrine, metabolic, and clinical parameters in patients with polycystic …

Introduction: Is the replacement of ethinyl-estradiol (EE) with estradiol (E2) in combined
hormonal contraceptives (CHCs) associated with fewer metabolic effects, leading to a further …

Background Fertile women may be encouraged to use contraception during clinical trials to
avoid potential drug effects on fetuses. However, hormonal contraception interferes with …